Preferred Label : Tiragolumab;
NCIt definition : A human monoclonal antibody targeting the co-inhibitory molecule and immune checkpoint
inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based
inhibitory motif (ITIM) domains (TIGIT), with potential immune checkpoint inhibitory
activity. Upon administration, tiragolumab binds to TIGIT expressed on various immune
cells, particularly on tumor-infiltrating T-lymphocytes (TILs), thereby preventing
the interaction of TIGIT with its ligands CD112 (nectin-2; poliovirus receptor related-2;
PVRL2) and CD155 (poliovirus receptor; PVR; nectin-like 5; NECL-5). This enhances
the interaction of CD112 and CD155 with the costimulatory receptor CD226 (DNAX Accessory
molecule-1; DNAM-1), which is expressed on immune cells, such as natural killer (NK)
cells and CD8 T-cells, and leads to CD226 dimerization and CD226-mediated signaling.
This activates the immune system to exert a T-cell-mediated immune response against
cancer cells. TIGIT, a member of the Ig super family and immune inhibitory receptor,
plays a key role in the suppression of T-cell proliferation and activation; it is
involved in tumor cell immune evasion, and the inhibition of antiviral immune responses.;
UNII : 6XG22YQM2Z;
CAS number : 1918185-84-8; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 1918185-84-8
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Molecule name : MTIG7192A; RG6058;
NCI Metathesaurus CUI : CL507941;
Origin ID : C131291;
UMLS CUI : C5235391;
Semantic type(s)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
